GENETIC TECHNOLOGIES LIMITED

QUARTERLY ACTIVITIES REPORT

FOR THE QUARTER ENDED 30 JUNE 2014

Melbourne, Australia; 31 July 2014: Molecular Diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to announce the return to growth in BREVAGenTM test samples received during the quarter ended 30 June 2014. Total patient samples received during the quarter were 1,096, representing 37% growth over the March 2014 quarter (800 samples). Domestic testing revenues, for the same period continued to exceed budget expectations.

OPERATIONS

Financial summary

Total cash receipts from customers during the quarter ended 30 June 2014 were $1.1 million taking the equivalent figure to $4.8 million for the full 2014 financial year ended on that date.

Domestic testing revenues for the quarter under review continue to exceed budget expectations, while revenue generated by the Company’s flagship test BREVAGen grew by 81% over the preceding March quarter. At June 30 2014 balance date, the company moved from cash to an accrual basis for recording revenue generated from the sale of the BREVAGen test product. This change resulted in a one-off upward adjustment to revenue of $416k.

BREVAGen™ breast cancer risk test

Test samples received for the full year to date:

The start of CY14 brought with it severe winter weather conditions across large tracts of the US and this restricted patient and physician physical access to medical centres and willingness to attend for anything other than urgent medical care. Further to this challenge, the holiday period coincided with the introduction of the Affordable Care Act, so-called ObamaCare, which created uncertainty in patients’ understanding of their out-of-pocket expense liability that also restricted the uptake of BREVAGen. With these factors removed, we saw a return of patients to doctors’ offices and improved preparedness to take preventative care decisions.

The June quarter completes the 2014 financial year for GTG, with 3,935 samples received in the financial year, more than double that received in the previous corresponding period.

GTG benefited during the quarter from an increased focus on breast centres, radiology groups and high-population, health-conscious territories, and this continued focused activity is anticipated to result in further growth over the coming quarters.

The launch of the next generation BREVAGen, “BREVAGen Plus” later this calendar year, is anticipated to result in accelerated sample test volume growth.

New Product Development:

Planning is well progressed and GTG is on target to release “BREVAGen Plus” in Q4, CY14. The new version of BREVAGen incorporates an expanded SNP (Single Nucleotide Polymorphism) panel, providing an increase in the predictive power of the test. Importantly, it will also be validated in Hispanic and African American women populations, thereby increasing the applicable market and simplifying the marketing process for BREVAGen in clinics and breast centres.

OPERATIONS - BREVAGen™ breast cancer risk test (cont.)

Reimbursement:

As mentioned in previous Activities Reports, until the end of 2012, insurance claims for BREVAGen were submitted using the so-called “code stack” of CPT methodology codes. Reimbursement under this regime was positive, with a low percentage of denials and appeals. However, effective 1 January 2013, the AMA removed the code stack claim process, requiring tests without a specific CPT code to be claimed via an “Unlisted or Miscellaneous Code”.

As a result of the above change for insurance claims, the Company’s reimbursement per test (including write-offs and denials for non-coverage) has increased by more than 30%. However, the use of a miscellaneous code requires more administration and time by the Insurance Company to adjudicate the claim and thus increasing the time taken to receive reimbursement.

Cost effectiveness studies to improve reimbursement outcomes:

Further to the publication in the journal of Cancer Prevention Research Vol 6 (12), dated 5 December 2013: pp 1328—36, demonstrating the cost effectiveness of the BREVAGen test to guide MRI screening, an additional paper has been published demonstrating the cost effectiveness of the BREVAGen test to direct chemoprevention.

On 7 March 2014, GTG announced the publication in the journal Applied Health Economics and Health Policy Vol 12 (2): pp 203—17, of a study entitled “Economic Evaluation of Using a Genetic Test to Direct Breast Cancer Chemoprevention in White Women With a Previous Breast Biopsy”. This study was a collaborative project between Genetic Technologies Limited and Archimedes Inc. of San Francisco, a healthcare modelling and analytics organization. The study examined the cost-effectiveness of utilizing BREVAGen to direct tamoxifen chemoprevention.

An in-silico model of breast cancer and health care processes was used to simulate a population of white women aged 40-69, who were at elevated risk for breast cancer due to a history of benign breast biopsy, in a virtual clinical trial. Women were assessed for risk of developing breast cancer using the BREVAGen test to determine eligibility for five years of tamoxifen therapy. The BREVAGen test was most cost-effective when given to patients at an intermediate risk of developing breast cancer (1.2 - 1.66% 5-year risk). The results demonstrated that adding genetic information about breast cancer susceptibility loci to current decision models for breast cancer chemoprevention not only improves clinical outcomes (with an average of 15 breast cancer cases prevented per 1,000 women), but is also cost-effective, with an incremental cost-effectiveness ratio below the benchmark number used by US payers of $50,000 per quality-adjusted life year (QALY) saved.

Clinical utility studies are currently being designed and will be commenced during the latter part of 2014. The data obtained in these studies will be utilised in the direct contracting discussions with Insurers and self-insured employer groups.

LICENSING AND IP

Non-coding Assertion Program

GTG is asserting actions against a number of different companies in 4 different States in the U.S.

On 24 December 2013, GTG reported that efficiencies in both legal resources and court times have been achieved by consolidating 4 cases, pending in the district of Delaware, in front of the same judge. The consolidation includes significant cases against companies such as Bristol Myers Squibb and Pfizer. These cases are awaiting scheduling orders but have been deferred until the court has ruled on 2 pending invalidity motions brought by 3 of the parties in September 2013 and in February 2014.

LICENSING AND IP - Non-coding Assertion Program (cont.)

On 12 March 2014, GTG announced that a further consolidation had been achieved in the Northern District of California where, following the transfer of the Natera case, it has been consolidated, for at least some of the proceeding with the Agilent case. Following the court’s ruling in favour of GTG, - denying the motion to dismiss based on invalidity, issued on 9 March 2014 - case scheduling and discovery procedures are underway.

In the Glaxo-SmithKline LLC (“GSK”) case in the District of North Carolina, GTG has filed a second amended complaint introducing infringement activities related to a second GTG patent. Subsequently, GSK has filed a motion to dismiss based on the familiar invalidity arguments raised by other parties. Further court activities will again be deferred until the ruling of the Judge in this matter.

Other licensing activities

There are no updates to report relating to the remaining U.S or European cases.

OTHER COMMERCIAL ASSETS

As part of GTG’s strategy to focus on the expansion of its cancer diagnostic franchise, work continues to sell, out-license, or partner other assets and technologies in which the Group has an interest.

ImmunAidTM

As previously reported, on 18 December 2013, GTG announced that entities associated with the Company’s founder and largest beneficial shareholder, Dr. Mervyn Jacobson (collectively, the “Jacobson Entities”), had entered into transactions which, when completed, will result in the disposal by them of 105,937,500 shares in the Company. Subsequent to that date, the Jacobson Entities disposed of 30,000,000 shares in GTG.

The Jacobson Entities and GTG entered into a binding Share Exchange Agreement (“Agreement”) pursuant to which, subject to GTG shareholder approval, the Jacobson Entities will exchange a total of 75,937,500 shares in GTG at an agreed price of $0.08 per share for 4,500,000 shares in ImmunAid Limited (“ImmunAid”) owned by GTG at an agreed price of $1.35 per share.

ImmunAid and GTG have also executed an Option Agreement pursuant to which ImmunAid will, when completion occurs under the Agreement, grant to GTG options to acquire a total of 2,250,000 ordinary shares in ImmunAid.

On 13 March 2014 GTG released the notice of the Extraordinary General Meeting of shareholders and Sample Proxy for the Meeting The notice of meeting also included the Independent Expert’s Report which was required to show all of the transactions above are fair and reasonable to Non-Associated Shareholders.

On 17 April 2014 the shareholders voted on the special resolution to approve the selective capital reduction by GTG and the disposal by GTG of shares in ImmunAid Limited. The resolution was passed on a show of hands.

OTHER COMMERCIAL ASSETS - ImmunAidTM (cont.)

On 16 May 2014, GTG announced the completion of Share transactions with Dr Mervyn Jacobson, at which time, the then number of ordinary issued shares in GTG was reduced by 11.4%, from 664,769,002 to 588,831,502, following the cancellation of the shares acquired from the Jacobson Entities. Following the transaction, the Jacobson Entities were left with a total holding of 30,536,184 ordinary shares in GTG, representing 5.19% of the Company’s then total issued capital.

CORPORATE MATTERS

Convertible Notes

On 29 November 2013, GTG received approval from its shareholders for the issue to Ironridge BioPharma Co., a division of institutional investor Ironridge Global IV, Ltd. (“Ironridge”), redeemable convertible notes to raise USD 5,000,000 (the “Notes”).

On 23 December 2013, the Notes were drawn down and GTG received $5,627,462 (being the Australian dollar equivalent of USD 5,000,000) from Ironridge, before the payment of associated costs.

As at 31 March 2014, Notes with a face value of USD 2,250,000 had been converted in return for which Ironridge has received 74,645,781 ordinary shares in GTG (including ordinary shares issued in lieu of interest payment). During the current quarter, further Notes with a face value of USD 1,000,000 were converted in return for which Ironridge received 42,516,090 ordinary shares (including ordinary shares issued in lieu of interest payment and an interest true-up adjustment). On 7 July 2014, Notes with a face value of USD 500,000 were converted in return for which Ironridge received 23,227,950 ordinary shares (including ordinary shares issued in lieu of interest payment). As a result of the above conversions, the face value of Notes remaining is reduced to USD 1,250,000.

Executive Moves and Appointments

As previously announced, the Company is pleased to confirm:

1. The return of Ms. Alison Mew to full-time work to resume her position of Chief Executive Officer, as from Tuesday, 1 April 2014; and

2. The appointment of Mr Eutillio Buccilli as Chief Financial Officer, effective 2 June 2014.

With Eutillio’s appointment, Acting Chief Financial Officer Ms .Bronwyn Christie relinquished this role on Friday, 30 May 2014 and thereby resumes her role of Financial Controller for the GTG Group while retaining the role of Company Secretary.

The Company wishes to thank Ms. Christie for her service and contribution during this time.

Signed on behalf of Genetic Technologies Limited

		Dated this 31th day of July, 2014
ALISON J. MEW
Chief Executive Officer

Appendix 4C

Quarterly report for entities

admitted on the basis of commitments

Rule 4.7B

Appendix 4C

Quarterly report

for entities admitted

on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001, 24/10/2005.

Name of entity

GENETIC TECHNOLOGIES LIMITED

ABN	Quarter ended (“current quarter”)
17 009 212 328	30 JUNE 2014

Consolidated statement of cash flows

			Current quarter (June 2014) A$		Year to date (twelve months) A$
	Cash flows related to operating activities
1.1	Receipts from customers		1,056,521		4,755,702
1.2	Payments for	(a) staff costs	(1,994,629	)	(7,801,333	)
		(b) advertising and marketing	(314,909	)	(1,082,448	)
		(c) research and development	(31,866	)	(31,866	)
		(d) leased assets	—		—
		(e) other working capital	(1,515,416	)	(6,371,584	)
1.3	Dividends received		—		—
1.4	Interest and items of a similar nature received		43,359		116,047
1.5	Interest and other costs of finance paid		(12,778	)	(52,550	)
1.6	Income taxes paid		—		—
1.7	Grant and other income		190,395		190,395
	Net operating cash flows		(2,579,323	)	(10,277,637	)

+ See chapter 19 for defined terms.

Appendix 4C Page 1

Consolidated statement of cash flows (cont.)

			Current quarter (June 2014) A$		Year to date (twelve months) A$
1.8	Net operating cash flows (carried forward)		(2,579,323	)	(10,277,637	)

	Cash flows related to investing activities
1.9	Payment for the acquisition of:
		a) businesses (item 5)	—		—
		b) equity investments	—		—
		c) intellectual property	—		—
		d) physical non-current assets	(20,804	)	(47,917	)
		e) other non-current assets	(114,159	)	(114,159	)

1.10	Proceeds from the disposal of:
		a) businesses (item 5)	—		—
		b) equity investments	—		—
		c) intellectual property	—		—
		d) physical non-current assets	—		—
		e) joint venture interest	—		—
		f) other assets	577,497		577,497

1.11	Loans to other entities		—		—
1.12	Loans repaid by other entities (refer note below)		—		—
1.13	Other (provide details if material)		—		(183,011	)
	Net investing cash flows		442,534		(232,410	)

1.14	Total operating and investing cash flows		(2,136,789	)	(10,045,227	)
	Cash flows related to financing activities
1.15	Net proceeds from the issue of shares		(21,282	)	6,341,502
1.16	Equity transaction costs		—		—
1.17	Net proceeds from borrowings		—		4,827,532
1.18	Advances to third parties		—		—
1.19	Dividends paid		—		—
1.20	Repayment of finance lease principal		—		—
	Net financing cash flows		(21,282	)	11,169,034

	Net increase / (decrease) in cash held		(2,158,071	)	1,123,807
1.21	Cash at beginning of quarter / year to date		4,993,347		1,721,293
1.22	Exchange rate adjustments		(4,191	)	(14,015	)
1.23	Cash at end of quarter		2,831,085		2,831,085

+ See chapter 19 for defined terms.

Appendix 4C Page 2

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

Non-cash financing and investing activities

2.1	Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

	None during the quarter under review

2.2	Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

	None during the quarter under review

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

		Amount available $A	Amount used $A
3.1	Loan facilities	—	—
3.2	Credit standby arrangements
	Hire purchase facility	—	—

+ See chapter 19 for defined terms.

Appendix 4C Page 3

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows:

		Current quart.er (June 2014) $A	Previous quarter (March 2014) $A
4.1	Cash on hand and at bank	2,831,085	1,743,347
4.2	Term deposits	—	3,250,000
4.3	Bank overdraft	—	—
4.4	Commercial Bills of Exchange	—	—
	Total cash at end of quarter (item 1.23)	2,831,085	4,993,347

Acquisitions and disposals of business entities

		Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1	Name of entity	Not applicable	Gtech International Resources Limited
5.2	Place of incorporation or registration		Yukon Territory, Canada
5.3	Consideration for acquisition or disposal		$nil
5.4	Total net liabilities		$9,172
5.5	Nature of business		Dormant

Compliance statement

1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.

2 This statement does give a true and fair view of the matters disclosed.

Sign here:		Date:	31 July 2014
	Chief Executive Officer


Print name:	Alison J. Mew

+ See chapter 19 for defined terms.

Appendix 4C Page 4

Exhibit 99.2

Appendix 3B

New issue announcement

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement,

application for quotation of additional securities

and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name of entity

GENETIC TECHNOLOGIES LIMITED

ABN

17 009 212 238

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1	+Class of +securities issued or to be issued	Unlisted options over ordinary shares issued pursuant to the Employee Share Option Plan approved by shareholders on 21 November 2011

2	Number of +securities issued or to be issued (if known) or maximum number which may be issued	6,875,000

3	Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)	Expiring 31 May 2019 with an exercise price of 4.0 cents each

+ See chapter 19 for defined terms.

Appendix 3B Page 1

4	Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities? If the additional securities do not rank equally, please state: · the date from which they do · the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment · the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	Yes

5	Issue price or consideration	Nil

6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	To provide an incentive and to align the interests of the recipients with those of the shareholders

6a	Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b — 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i	No

6b	The date the security holder resolution under rule 7.1A was passed	Not applicable

6c	Number of +securities issued without security holder approval under rule 7.1	Not applicable

6d	Number of +securities issued with security holder approval under rule 7.1A	Not applicable

6e	Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Not applicable

6f	Number of securities issued under an exception in rule 7.2	6,875,000

+ See chapter 19 for defined terms.

Appendix 3B Page 2

6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	Not applicable

6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	Not applicable

6i	Calculate the entity’s remaining issue capacity under rule 7.1 and rule 7.1A — complete Annexure 1 and release to ASX Market Announcements	49,123,672

7	Dates of entering +securities into uncertificated holdings or despatch of certificates	31 July 2014

		Number	+Class
8	Number and +class of all +securities quoted on ASX (including the securities in section 2 if applicable)	637,146,442	Ordinary shares

		Number	+Class
9	Number and +class of all +securities not quoted on ASX (including the securities in section 2 if applicable)	1,875,000	Options at $0.19, exp. 31/3/2016 (GTGAW)

		1,000,000	Options at $0.20, exp.
			31/7/2016 (GTGAM)

		750,000	Options at $0.12, exp.
			20/2/2017 (GTGAK)

		2,650,000	Options at $0.14, exp.
			29/8/2017 (GTGAO)

		250,000	Options at $0.10, exp.
			1/12/17 (GTGAQ)

		500,000	Options at $0.10, exp.
			25/1/18 (GTGAS)

		750,000	Options at $0.105, exp.
			11/7/18 (GTGAY)

		6,875,000	Options at $0.04, exp. 31/5/19 (NEW)

		12,500,000	Convertible Note issued on 19 December 2013

+ See chapter 19 for defined terms.

Appendix 3B Page 3

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Not applicable

Part 2 - Bonus issue or pro rata issue

11		Is security holder approval required?

12		Is the issue renounceable or non-renounceable?

13		Ratio in which the +securities will be offered

14		+Class of +securities to which the offer relates

15		+Record date to determine entitlements

16		Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?

17		Policy for deciding entitlements in relation to fractions

18		Names of countries in which the entity has +security holders who will not be sent new issue documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.

19		Closing date for receipt of acceptances or renunciations

20		Names of any underwriters

21		Amount of any underwriting fee or commission

22		Names of any brokers to the issue

23		Fee or commission payable to the broker to the issue

24		Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of +security holders

+ See chapter 19 for defined terms.

Appendix 3B Page 4

25		If the issue is contingent on +security holders’ approval, the date of the meeting

26		Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled

27		If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders

28		Date rights trading will begin (if applicable)

29		Date rights trading will end (if applicable)

30		How do +security holders sell their entitlements in full through a broker?

31		How do +security holders sell part of their entitlements through a broker and accept for the balance?

32		How do +security holders dispose of their entitlements (except by sale through a broker)?

33		+Despatch date

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34	Type of securities (tick one)

(a)	x	Securities described in Part 1

(b)	o	All other securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

+ See chapter 19 for defined terms.

Appendix 3B Page 5

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35	o	If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders

36	o	If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over

37	o	A copy of any trust deed for the additional +securities

Entities that have ticked box 34(b)

38	Number of securities for which +quotation is sought

39	Class of +securities for which quotation is sought

40	Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities? If the additional securities do not rank equally, please state: · the date from which they do · the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment · the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another security, clearly identify that other security)

		Number	+Class
42	Number and +class of all +securities quoted on ASX (including the securities in clause 38)

+ See chapter 19 for defined terms.

Appendix 3B Page 6

Quotation agreement

1 +Quotation of our additional +securities is in ASX’s absolute discretion. ASX may quote the +securities on any conditions it decides.

2 We warrant the following to ASX.

· The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.

· There is no reason why those +securities should not be granted +quotation.

· An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

· Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.

· If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:		Date: 31 July 2014
	Chief Financial Officer


Print name:	Eutillio Buccilli

== == == == ==

+ See chapter 19 for defined terms.

Appendix 3B Page 7

Appendix 3B — Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for +eligible entities

Introduced 01/08/12

Part 1

Rule 7.1 — Issues exceeding 15% of capital

Step 1: Calculate “A”, the base figure from which the placement capacity is calculated

*Insert* number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue		475,471,819

*Add* the following:

· Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2		19,277,857

· Number of fully paid ordinary securities issued in that 12 month period with shareholder approval		177,944,445

· Number of partly paid ordinary securities that became fully paid in that 12 month period

Note: · Include only ordinary securities here — other classes of equity securities cannot be added · Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed · It may be useful to set out issues of securities on different dates as separate line items

*Subtract* the number of fully paid ordinary securities cancelled during that 12 month period		75,937,500

“A”		596,756,621

*Step 2: Calculate 15% of “A”*

“B”		0.15 [Note: this value cannot be changed]

*Multiply* “A” by 0.15		89,513,493

+ See chapter 19 for defined terms.

Appendix 3B Page 8

*Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used*

*Insert* number of equity securities issued or agreed to be issued in that 12 month period not counting those issued: · Under an exception in rule 7.2 · Under rule 7.1A · With security holder approval under rule 7.1 or rule 7.4 Note: · This applies to equity securities, unless specifically excluded — not just ordinary securities · Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed · It may be useful to set out issues of securities on different dates as separate line items

“C”		40,389,821

*Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1*

“A” x 0.15 Note: number must be same as shown in Step 2		89,513,493

*Subtract* “C” Note: number must be same as shown in Step 3		40,389,821

*Total* [“A” x 0.15] — “C”		49,123,672 [Note: this is the remaining placement capacity under rule 7.1]

+ See chapter 19 for defined terms.

Appendix 3B Page 9

Part 2

Rule 7.1A — Additional placement capacity for eligible entities

Step 1: Calculate “A”, the base figure from which the placement capacity is calculated

“A” Note: number must be same as shown in Step 1 of Part 1

*Step 2: Calculate 10% of “A”*

“D”		0.10 Note: this value cannot be changed

*Multiply* “A” by 0.10

*Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used*

*Insert* number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A Notes: · This applies to equity securities — not just ordinary securities · Include here — if applicable — the securities the subject of the Appendix 3B to which this form is annexed · Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained · It may be useful to set out issues of securities on different dates as separate line items

“E”

+ See chapter 19 for defined terms.

Appendix 3B Page 10

GENETIC TECHNOLOGIES LIMITED


By:	/s/ Bronwyn Christie
	Name:	Bronwyn Christie
	Title:	Company Secretary

Exhibit		Description of Exhibit

99.1		Quarterly Activities Report and Appendix 4C of the ASX Listing Rules for the quarter ended 30 June 2014

99.2		Appendix 3B, 31 July 2014

“A” x 0.10 Note: number must be same as shown in Step 2

*Subtract* “E” Note: number must be same as shown in Step 3

*Total* [“A” x 0.10] — “E”		Note: this is the remaining placement capacity under rule 7.1A

Current quarter
$A

Aggregate amount of payments to the parties included in item 1.2

119,882

Aggregate amount of loans to the parties included in item 1.11

Explanation necessary for an understanding of the transactions

The amount included at Item 1.24 includes $82,382 paid to Directors during the quarter in respect of fees and superannuation. The amount also includes $37,500 in commissions and consulting fees paid to a former Director and substantial shareholder in respect of services rendered to the Company by that individual and parties associated with him.